Background
Methods
β-Hexosaminidase activity assessment
Molecular study
Result
Demographic findings and clinical course
Patients NO | Age(m) | Age at (m) presentation | Age(m) diagnosis | Delay Of diagnosis (m) | Sex | Consanguineous Marriage | FH of Sandhoff Disease | History of previous disease | History of maternal abortion | FH of unexplained death | Dead/Alive |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 12 | 5 | 10 | 5 | F | + | – | NI | – | – | Alive |
2 | 16 | 10 | 11 | 1 | F | + | + | NI | + | + | Alive |
3 | 20 | 6 | 20 | 16 | M | + | – | NI | – | + | Dead |
4 | 18 | 7 | 18 | 11 | M | + | – | – | – | – | Alive |
5 | 10 | 3 | 10 | 7 | M | – | – | – | – | – | Dead |
6 | 12 | 7 | 11 | 4 | F | + | – | – | – | – | Dead |
7 | 20 | 9 | 19 | 10 | F | – | – | – | – | – | Alive |
8 | 20 | 12 | 20 | 8 | M | + | – | – | – | – | Dead |
9 | 9 | 5 | 9 | 4 | F | + | – | – | – | – | Dead |
10 | 22 | 6 | 22 | 16 | M | + | – | – | – | – | Dead |
11 | 20 | 6 | 18 | 12 | F | + | – | – | – | – | Dead |
12 | 18 | 6 | 18 | 12 | F | + | – | – | – | – | Dead |
13 | 14 | 2 | 12 | 10 | F | + | – | NI | – | – | Alive |
14 | 18 | 6 | 16 | 6 | F | – | – | – | – | – | Dead |
15 | 14 | 4 | 14 | 10 | F | – | – | – | – | – | Alive |
16 | 20 | 2 | 20 | 18 | M | + | – | – | – | + | Alive |
17 | 22 | 12 | 10 | 6 | F | + | – | – | – | + | Alive |
18 | 13 | 12 | 13 | 1 | M | + | – | NI | – | – | Alive |
19 | 12 | 5 | 12 | 7 | M | + | – | – | + | + | Alive |
20 | 11 | 9 | 11 | 2 | M | + | – | NI | – | + | Dead |
21 | 12 | 6 | 10 | 4 | M | – | – | – | – | – | Alive |
22 | 13 | 4 | 13 | 9 | F | + | – | – | – | + | Alive |
23 | 12 | 6 | 12 | 6 | F | + | – | – | – | + | Alive |
24 | 10 | 4 | 10 | 6 | M | + | + | – | – | – | Alive |
25 | 24 | 6 | 12 | 6 | M | + | + | – | – | + | Dead |
Presenting symptoms
Number of case | Age of developmental delay (m) | Age of developmental regression (m) | Age of Cognitive delay (m) | Age of poor fix and follow (m) | Age of hypotonia(m) | Age of seizure (m) | Age of delay speach |
---|---|---|---|---|---|---|---|
1 | 4 | 7 | 8 | 2 | 5 | – | 10 |
2 | 9 | 10 | 9 | – | 4 | – | 12 |
3 | 5 | 8 | 10 | – | 4 | – | 12 |
4 | 5 | 8 | 9 | – | 6 | 4 | 10 |
5 | 3 | 9 | 8 | – | 7 | – | 9 |
6 | 6 | 8 | 9 | 3 | 5 | – | 9 |
7 | 4 | 7 | 9 | – | – | – | 10 |
8 | – | 7 | 11 | – | 5 | – | 11 |
9 | 7 | 10 | 8 | – | – | 6 | – |
10 | 5 | 7 | 9 | – | – | 5 | 13 |
11 | 6 | 8 | 10 | – | 6 | 6 | 14 |
12 | 6 | 9 | 8 | – | 5 | 7 | 11 |
13 | 2 | 6 | 9 | – | 7 | 6 | 10 |
14 | 5 | 9 | 10 | – | 5 | 8 | 13 |
15 | – | 8 | 10 | – | – | – | 10 |
16 | 4 | 9 | 12 | – | 6 | 3 | 12 |
17 | 5 | 7 | 13 | 2 | – | – | 12 |
18 | – | 9 | – | 4 | 5 | – | – |
19 | 4 | 8 | 9 | – | 6 | – | 10 |
20 | 5 | – | 8 | – | 4 | – | 9 |
21 | 5 | – | 9 | – | – | – | – |
22 | 4 | 7 | 9 | – | 6 | – | 10 |
23 | 5 | 9 | 9 | – | 5 | – | 10 |
24 | 4 | 7 | 8 | – | 4 | – | 8 |
25 | 5 | 8 | 12 | – | 4 | – | 10 |
Clinical findings
Neuroimaging findings
Patient No | Brain MRI |
---|---|
5 | Hypomyelination, caudate, GP, putamen involvement |
9 | Hypo and delayed myelination, putamen, GP and caudate involvement, Turkish mustache |
10 | Hypomyelination, putamen, GP and caudate involvement, Turkish mustache |
11 | Hypo and delayed myelination, putamen, GP and caudate involvement, Turkish mustache |
12 | Hypo and delayed myelination, putamen, GP and caudate involvement |
14 | Hypo and delayed myelination, putamen, GP and caudate involvement, Turkish mustache |
16 | Hypo and delayed myelination, demyelination, putamen, GP and caudate involvement, Turkish mustache |
21 | Hypomyelination, caudate, GP, putamen involvement |
24 | Hypomyelination, caudate, GP, putamen involvement |
25 | Hypomyelination, caudate, GP, putamen involvement |
Laboratory findings and HEXB mutations
Patient No | Hexosaminidase A | Hexosaminidase B | Hexosaminidase AB | Mutations | Novel mutations |
---|---|---|---|---|---|
1 | 0.27 | 0.09 | 1.00 | c.1602C > A (p.Cys534Ter) | + |
2 | 0.18 | 0.00 | 0.5 | c.833C > T (P.Ala278Val) | + |
3 | 0.23 | 0.03 | 0.72 | c.850C > T (p.Arg284Ter) | Zampieri 2009 [19] |
4 | 0.12 | 0.78 | 0.46 | c.1641_1657del | + |
5 | 0.25 | 0.62 | 1.88 | – | – |
6 | 0.13 | 0.04 | 0.5 | c.833C > T(p.Ala278val) | + |
7 | 0.18 | 0.02 | 0.57 | – | – |
8 | 0.06 | 0.02 | 0.00 | – | – |
9 | 0.16 | 0.00 | 0.2 | – | – |
10 | 0.18 | 0.10 | 0.03 | – | – |
11 | 0.06 | 0.33 | 0.2 | – | – |
12 | 0.1 | 0.8 | 0.5 | – | |
13 | 0.15 | 0.03 | 0.53 | c.668_669 + 4dupTGGTAA | + |
14 | 0.07 | 0.52 | 0.3 | – | – |
15 | 0.28 | 0.00 | 0.6 | – | – |
16 | 0.03 | 0.01 | 0.01 | – | – |
17 | 0.26 | 0.42 | 1 | – | – |
18 | 0.01 | 0.01 | 0.06 | c.1538 T > c(rs778501777;p.leu513pro) | Lee et al. 2017 [7] |
19 | 0.16 | 0.00 | 0.41 | c.850 > T (p.Arg284Ter) | Zampieri 2009 [19] |
20 | 0.16 | 0.00 | 0.67 | – | – |
21 | 0.21 | 0.03 | 0.98 | – | – |
22 | 0.08 | 0.00 | 0.3 | – | – |
23 | 0.20 | 0.10 | 0.6 | – | – |
24 | 0.04 | 0.19 | 0.00 | – | – |
25 | 0.23 | 0.00 | 0.8 | – | – |